Tg Therapeutics (TGTX) Amortization of Deferred Charges (2018 - 2025)
Historic Amortization of Deferred Charges for Tg Therapeutics (TGTX) over the last 8 years, with Q3 2025 value amounting to $304000.0.
- Tg Therapeutics' Amortization of Deferred Charges fell 2657.0% to $304000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 4787.64%. This contributed to the annual value of $2.0 million for FY2024, which is 1610.6% down from last year.
- Per Tg Therapeutics' latest filing, its Amortization of Deferred Charges stood at $304000.0 for Q3 2025, which was down 2657.0% from $304000.0 recorded in Q2 2025.
- Tg Therapeutics' Amortization of Deferred Charges' 5-year high stood at $639000.0 during Q2 2023, with a 5-year trough of $231000.0 in Q1 2021.
- In the last 5 years, Tg Therapeutics' Amortization of Deferred Charges had a median value of $461000.0 in 2022 and averaged $435684.2.
- In the last 5 years, Tg Therapeutics' Amortization of Deferred Charges skyrocketed by 9956.71% in 2022 and then plummeted by 5258.22% in 2024.
- Tg Therapeutics' Amortization of Deferred Charges (Quarter) stood at $386000.0 in 2021, then grew by 19.43% to $461000.0 in 2022, then soared by 38.61% to $639000.0 in 2023, then tumbled by 52.58% to $303000.0 in 2024, then rose by 0.33% to $304000.0 in 2025.
- Its last three reported values are $304000.0 in Q3 2025, $304000.0 for Q2 2025, and $304000.0 during Q1 2025.